IBD IBD Pharmacotherapy 3

Question 1

Therapeutic drug monitoring (TDM) of infliximab targets which minimum trough level for maintaining remission in IBD?

Accepted Answer

3–7 µg/mL

Answer

<1 µg/mL

Answer

>15 µg/mL

Answer

10–20 µg/mL

Question 2

Which new IL-23 p19 specific inhibitor was FDA-approved for Crohn's disease, offering more selectivity than ustekinumab?

Accepted Answer

Risankizumab (Skyrizi)

Answer

Guselkumab

Answer

Tildrakizumab

Answer

Secukinumab

Question 3

Fecal microbiota transplantation (FMT) has shown the most promising evidence for treating which IBD-related condition?

Accepted Answer

Recurrent C. difficile infection in IBD patients

Answer

Active Crohn's disease

Answer

Refractory UC flares

Answer

Pouchitis after IPAA

Question 4

Cyclosporine IV is used as rescue therapy in severe acute UC refractory to IV corticosteroids. What is its primary mechanism?

Accepted Answer

Calcineurin inhibition → reduced IL-2 → T-cell suppression

Answer

Blocking TNF-α at the mucosal level

Answer

Inhibiting B-cell antibody production

Answer

Blocking integrin-mediated lymphocyte trafficking

Question 5

Ozanimod, approved for UC, works through which novel mechanism?

Accepted Answer

Sphingosine-1-phosphate (S1P) receptor modulation, sequestering lymphocytes in lymph nodes

Answer

Blocking TNF-α

Answer

Inhibiting JAK2 selectively

Answer

Blocking IL-6 trans-signaling

Question 6

Which medication is recommended for preventing post-operative Crohn's disease recurrence after ileocolonic resection?

Accepted Answer

Anti-TNF therapy (e.g., infliximab) or thiopurines based on risk stratification

Answer

Mesalamine alone

Answer

No treatment needed post-operatively

Answer

Corticosteroids for 6 months